


## Etoricoxib

## Chemical Properties

CAS No. :	202409-33-4
Formula:	C <sub>18</sub> H <sub>15</sub> ClN <sub>2</sub> O <sub>2</sub> S
Molecular Weight:	358.84
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Etoricoxib (MK-663) is a synthetic, nonsteroidal anti-inflammatory drug (NSAID) with antipyretic, analgesic, and potential antineoplastic properties. Etoricoxib specifically binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in inhibition of the conversion of arachidonic acid into prostaglandins. Inhibition of COX-2 may induce apoptosis and inhibit tumor cell proliferation and angiogenesis.
Targets(IC50)	COX
In vivo	The preferential cyclooxygenase-2 inhibitor etoricoxib significantly reduces the anticonvulsant action of phenytoin and significantly increases the beneficial action of diazepam against maximal electroshock and pentylenetetrazole-induced convulsions in a mouse model[1]. Etoricoxib has the potential to act as an anti-apoptotic and anti-proliferative agent in the colon[2].
Cell Research	Human colon carcinoma cell line HCT-116 are treated with various coxibs for 2 h. Subsequently, the cells are harvested and the sphingolipids isolated and determined by LC-MS/MS. (Only for Reference)

## Solubility Information

Solubility	Ethanol: 43 mg/mL (119.83 mM),Sonication is recommended. DMSO: 252 mg/mL (702.26 mM),Sonication is recommended. H <sub>2</sub> O: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (13.93 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.7868 mL	13.9338 mL	27.8676 mL
5 mM	0.5574 mL	2.7868 mL	5.5735 mL
10 mM	0.2787 mL	1.3934 mL	2.7868 mL
50 mM	0.0557 mL	0.2787 mL	0.5574 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Jayaraman R, et al. J Pharm Pharmacol. 2010, 62(5):610-4.

Tanwar L, et al. Asian Pac J Cancer Prev. 2010, 11(5):1329-33.

Schiffmann S, et al. J Lipid Res. 2009, 50(1):32-40.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481